Theorem Clinical Research

Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


CORD:USE, Tianhe Stem Cell Biotechnologies partner

Thursday, October 2, 2014 02:20 PM

CORD:USE Cord Blood Bank, headquartered in Orlando, Fla., an operator of both public and family cord blood banks, has entered into an agreement with Illinois–based Tianhe Stem Cell Biotechnologies, which has licensed a series of patented technologies for the isolation of human cord blood-derived multipotent stem cells for possible clinical applications.

More... »


National MS Society invests nearly $19 million in MS research

Thursday, October 2, 2014 02:16 PM

The National Multiple Sclerosis (MS) Society has committed nearly $19 million to support an expected 54 new MS research projects. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost and ending the disease forever.

More... »


BioNTech, Ganymed Pharmaceuticals open research headquarters in Germany

Thursday, October 2, 2014 02:14 PM

BioNTech and Ganymed Pharmaceuticals, two German biotechology companies, have opened a 108,000-square-foot headquarters and research facility. The new facility brings together 300 employees and is located near academic institutions, hospitals and cancer research institutions.

More... »

NCI co-funding Pharmatech Just-In-Time expansion

Thursday, October 2, 2014 02:13 PM

The National Cancer Institute (NCI) is co-funding Denver, Colo.-based CRO Pharmatech’s development of AccessPPM and expansion of its Just-In-Time enrollment programs.

More... »

NHS chief Simon Stevens launches $1M prize fund for innovation

Thursday, October 2, 2014 02:11 PM

Simon Stevens, NHS chief executive, has launched a $1 million prize pot to reward innovation in the NHS. The NHS Innovation Challenge Prize encourages, celebrates and rewards innovation driven by the frontline doctors, nurses and NHS staff who deliver care every day. 

More... »

NIBSC signs agreement with UCL

Thursday, October 2, 2014 02:09 PM

A memorandum of understanding has been signed between the National Institute for Biological Standards and Control and University College London (UCL). The memorandum states that both parties should share common goals to help safeguard and enhance public health in the U.K. and elsewhere. Best available science should be applied to the international harmonization of standards for characterization, production and distribution, and the availability of cell lines and other key materials of appropriate quality for research and clinical use should be facilitated.

More... »

Glialogix, National Multiple Sclerosis Society collaborate

Thursday, October 2, 2014 02:08 PM

Glialogix, a San Francisco Bay Area-based emerging biopharma company, has entered into a sponsored research agreement with Fast Forward, a nonprofit organization established by the New York-based National Multiple Sclerosis (MS) Society to accelerate the development of treatments for MS. Fast Forward will provide funding for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS.

More... »

Noven receives FDA new indication approval for Minivelle

Thursday, October 2, 2014 02:01 PM

Noven Pharmaceuticals has announced that the FDA has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. With this new approval, women who are using Minivelle to treat their VMS symptoms have the benefit of also helping to prevent osteoporosis.

More... »

CytRx receives multiple FDA Orphan Drug designations for Aldoxorubicin

Thursday, October 2, 2014 01:50 PM

CytRx, a biopharmaceutical R&D company specializing in oncology, has announced that the FDA has granted multiple Orphan Drug designations for the company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. Aldoxorubicin is CytRx's modified version of the widely-used chemotherapeutic agent, doxorubicin.

More... »

BioClinica Compass wins technology innovation award

Thursday, October 2, 2014 01:32 PM

BioClinica, a provider of outsourced clinical trial services and eClinical Solutions, has announced that its Compass technology, a risk-based monitoring solution that improves overall quality in clinical trials, has won the inaugural Society for Clinical Data Management (SCDM) NextGen Technology Innovation (TIA) Award, presented as part of SCDM's 2014 annual conference.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs